Last reviewed · How we verify
Tenofovir, emtricitabine, lopinavir/r
Tenofovir, emtricitabine, lopinavir/r is a Antiretroviral combination (NRTI + PI) Small molecule drug developed by Hospital Clinic of Barcelona. It is currently FDA-approved for HIV-1 infection.
This combination inhibits HIV reverse transcriptase and protease to block viral replication at multiple steps.
This combination inhibits HIV reverse transcriptase and protease to block viral replication at multiple steps. Used for HIV-1 infection.
At a glance
| Generic name | Tenofovir, emtricitabine, lopinavir/r |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Antiretroviral combination (NRTI + PI) |
| Target | HIV reverse transcriptase, HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tenofovir and emtricitabine are nucleoside reverse transcriptase inhibitors (NRTIs) that block the enzyme responsible for converting HIV RNA into DNA. Lopinavir/ritonavir is a protease inhibitor that prevents the maturation of HIV virions by inhibiting the viral protease enzyme. Together, they suppress HIV replication through complementary mechanisms.
Approved indications
- HIV-1 infection
Common side effects
- Diarrhea
- Nausea
- Lipid abnormalities (elevated triglycerides/cholesterol)
- Abdominal pain
- Headache
- Renal dysfunction (tenofovir-related)
- Bone density loss
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (NA)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (PHASE2)
- Study of Options for Second-Line Effective Combination Therapy (SELECT) (PHASE3)
- RESIST-2: 2nd-line ART for HIV-2 Infection (NA)
- Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir, emtricitabine, lopinavir/r CI brief — competitive landscape report
- Tenofovir, emtricitabine, lopinavir/r updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI
Frequently asked questions about Tenofovir, emtricitabine, lopinavir/r
What is Tenofovir, emtricitabine, lopinavir/r?
How does Tenofovir, emtricitabine, lopinavir/r work?
What is Tenofovir, emtricitabine, lopinavir/r used for?
Who makes Tenofovir, emtricitabine, lopinavir/r?
What drug class is Tenofovir, emtricitabine, lopinavir/r in?
What development phase is Tenofovir, emtricitabine, lopinavir/r in?
What are the side effects of Tenofovir, emtricitabine, lopinavir/r?
What does Tenofovir, emtricitabine, lopinavir/r target?
Related
- Drug class: All Antiretroviral combination (NRTI + PI) drugs
- Target: All drugs targeting HIV reverse transcriptase, HIV protease
- Manufacturer: Hospital Clinic of Barcelona — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection
- Compare: Tenofovir, emtricitabine, lopinavir/r vs similar drugs
- Pricing: Tenofovir, emtricitabine, lopinavir/r cost, discount & access